While both EXT1 and EXT2 were found to be upregulated in gliomas, we prioritized EXT1 for immunohistochemical (IHC) validation due to its stronger transcriptomic association with immune suppression, stromal activation, and clinical outcomes. The gene discussed is EXT2; the disease is central nervous system cancer.